CYCN
NASDAQ · Biotechnology
Cyclerion Therapeutics Inc
$1.10
+0.02 (+1.85%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.25M | 1.11M | 1.23M |
| Net Income | -199,437 | -131,808 | -179,754 |
| EPS | — | — | — |
| Profit Margin | -15.9% | -11.8% | -14.7% |
| Rev Growth | +24.3% | +14.6% | +14.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 850.6K | 868.7K | 867.2K |
| Total Equity | 1.42M | 1.44M | 1.67M |
| D/E Ratio | 0.60 | 0.60 | 0.52 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -171,643 | -161,572 | -173,205 |
| Free Cash Flow | -146,884 | -153,109 | -131,610 |